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CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2,
ﬂuorouracil 600 mg/m2) in 19 women or FAC (ﬂuorouracil
500 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/
m2) in 42 women. Alltogether 61 women were included into
study. Frequency and gradus of unwanted effects were measured
during ﬁve days after one arrival for the treatment. Neuthropenia
was measured by counting white blood cells 18–20 days after
chemotherapy. Diarrhoea, nausea and vomiting were graduated
by counting of number of episodes per day for ﬁve days after
each treatment. For each protocol the costs of treatment for
cytostatics as well as for treatment of unwanted effects and need
for prolonged hospitalisation were calculated. RESULTS: There
was a higher incidence of nausea, vomiting and neuthropenia in
FAC vs. CMF treatments (73.81%, 23.57%, 21.43% vs.
57.98%, 15.79%, 10.53%) and higher incidence of diarrhoea in
CMF vs. FAC treatments (5.68% vs. 2.38%). Anthracycline-
based protocols (FAC) caused greater severity of nausea, vomit-
ing and diarrhoea than CMF with equaly severe neuthropenia.
Drugs used for treatment of nausea, vomiting and neuthropenia
were setrons, corticosteroids and metoclopramide. The cost for
the one treatment episode for cytostatics were higher for FAC
(66.94 EU pre single dose, 401.64 EU for the whole cycle) than
for CMF (19,10 EU per single dose, 229.20 EU for whole cycle).
The costs of drugs used for the treatment of AEs were 13.20 EU/
patient/episode reciving CMF and 17.24 EU/patient/episode
reciving FAC protocol. CONCLUSIONS: CMF is safer and
cheaper than FAC protocol.
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OBJECTIVES: The MA17 trial showed that addition of letrozole
after 5 years tamoxifen was effective in further reducing the risk
of relapse in women with breast cancer. Recent data also indicate
that the cost of breast cancer relapse is much higher than previ-
ously shown, which has important implications for the beneﬁt of
adjuvant treatment. Further, the cost-effectiveness of adjuvant
treatment from a societal perspective and in the Nordic countries
is so far not extensively assessed. The objective of this study was
to assess cost-effectiveness of extending the adjuvant therapy in
Sweden, from a societal perspective. METHODS: Consequences
for a woman at the age of 62 years who have completed 5 years
tamoxifen treatment were assessed, from a societal and health
care perspective. Clinical data on risk of relapse and adverse
events were based on the MA17 trial. Costs, health utilities and
survival data were based on recent detailed Swedish data. A
reduction in relapse risk was extrapolated into a survival beneﬁt,
by assuming a higher mortality for patients with relapse.
RESULTS: The total societal cost for letrozole- and placebo-
treated patients were €7700 and €6300, respectively, a difference
of €1500. The difference in life-years and QALYs were 0.23 and
0.18, respectively, leading to costs of €6500 per life-years gained
and €8300 per QALY gained. The corresponding cost-
effectiveness ratios from a health care perspective were €10,500
per life-years gained and €13,400 per QALY gained. CONCLU-
SIONS: The study indicates that the incremental cost per QALY
gained for extended letrozole treatment in Sweden is low, and
hence indicates that money spent of extending the adjuvant treat-
ment with letrozole probably is money well spent in Sweden.
More long-term data on the overall survival gain would be
valuable to further validate the assumption used in the analysis.
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OBJECTIVES: To predict the expected incremental costs and
mean life-years associated with adding bevacizumab to
FOLFOX4 in the adjuvant treatment of patients with AJCC/
UICC stage III colon carcinoma following surgical resection.
METHODS: A three-health state (disease-free survival [DFS],
relapse/new occurrence of colon carcinoma, and death) Markov
model was used to explore the effects of adding one year of
adjuvant treatment with bevacizumab to the existing adjuvant
FOLFOX4 treatment regimen. Baseline DFS for FOLFOX4-
treated patients was based on published data from the MOSAIC
trial (André et al 2004). The relative risk reduction for bevaci-
zumab was based on protocol assumptions for the ongoing phase
III AVANT study. Outcomes included life-years, QALYs, direct
costs, and incremental cost-effectiveness ratios (ICERs) expressed
as costs per QALY or life-year gained. A life time horizon (40
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